Mean Corpuscular Haemoglobin Concentration and Outcomes in Heart Failure with Preserved Ejection Fraction
Authors:
Open Access
- 25 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (2) , 1214-1221
Abstract
Aims: This study aims to evaluate the prognostic value of mean corpuscular haemoglobin concentration (MCHC) on clinical outcomes in patients with heart failure with preserved ejection fraction (HFpEF). Methods and results: We analysed HFpEF participants from the Americas in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial with available baseline data (n = 1747). Patients were grouped into hypochromia or non-hypochromia group according to a MCHC cut-off level of 330 g/L. Cox proportional hazard model was used to explore the prognostic value of hypochromia on the long-term clinical outcomes (the primary endpoint [composite of cardiovascular mortality, HF hospitalization and aborted cardiac arrest], any-cause and HF hospitalization, all-cause and cardiovascular mortality). Patients were further stratified according to baseline estimated glomerular filtration rate (eGFR) to explore the impact of renal dysfunction on the prognostic value of hypochromia. Baseline hypochromia was prevalent (n = 662, 37.9%) and strongly associated with worse clinical outcomes. In patients with worse renal function (eGFR < 60 mL/min per 1.73 m2), hypochromia was independently associated with primary endpoint (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.23–1.98; P < 0.001), any-cause hospitalization (HR, 1.43; 95% CI, 1.20–1.71, P < 0.001) and HF hospitalization (HR, 1.40; 95% CI, 1.07–1.84; P = 0.015), whereas no significant association between hypochromia and these outcomes was found in patients with better renal function. Conclusions: Among HFpEF patients, hypochromia (i.e. MCHC ≤ 330 g/L) is independently associated with adverse clinical outcomes, especially when in the presence of co-morbidity renal dysfunction.Keywords
Funding Information
- China Postdoctoral Science Foundation (2021M693615)
- National Natural Science Foundation of China (82100387)
- Natural Science Foundation of Guangdong Province (2022A1515010227)
- Natural Science Foundation of Guangdong Province (2022A1515010785)
- Natural Science Foundation of Guangdong Province (2020A1515011095)
- High Level-Hospital Program, Health Commission of Guangdong Province, China (HKUSZH201902002)
- Shenzhen Science and Technology Innovation Commission (JCY20210324114808024)
- Postdoctoral Research Foundation of China (2021M693615)
- National Natural Science Foundation of China (82100387)
- Natural Science Foundation of Guangdong Province (2022A1515010227)
- Natural Science Foundation of Guangdong Province (2022A1515010785)
- Natural Science Foundation of Guangdong Province (2020A1515011095)
- Science, Technology and Innovation Commission of Shenzhen Municipality (JCY20210324114808024)
This publication has 25 references indexed in Scilit:
- Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysisInternational Journal of Cardiology, 2013
- Iron deficiency in chronic heart failure: An international pooled analysisAmerican Heart Journal, 2013
- Prognostic Implications of Relative Hypochromia in Ambulatory Patients With Chronic Systolic Heart FailureCongestive Heart Failure, 2012
- Disordered Iron Homeostasis in Chronic Heart FailureJACC, 2011
- Epidemiology of Anemia in Heart FailureHeart Failure Clinics, 2010
- Hepcidin—A Potential Novel Biomarker for Iron Status in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron DeficiencyJACC, 2008
- Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal InsufficiencyJACC, 2007
- Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificityNephrology Dialysis Transplantation, 2007
- Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammationBlood, 2003